Shots:

• The sNDA is based on the P-III JUPITER-06 study evaluating toripalimab + CT vs PBO + CT in 514 patients with locally advanced or metastatic ESCC
• The results of the study showed that toripalimab + CT significantly improved both PFS and OS for patients with advanced or metastatic ESCC- regardless of PD-L1 expression status. The data will be presented soon at ESMO 2021
• Toripalimab is the first domestic anti-PD-1 mAb obtaining marketing approval in China and has additionally received BTD- FTD & ODD from FDA for the treatment of mucosal melanoma- nasopharyngeal carcinoma- and soft tissue sarcoma

  | Ref: Globe Newswire | Image: PR Newswire